Live moderated video webcast with members of Management to discuss pivotal Phase 3 study of lead asset in development, LB1148, on Friday, September 16th at 11:00 AM ET

CARLSBAD, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that Tom Hallam, Ph.D., Chief Executive Officer and Michael Dawson, M.D., Chief Medical Officer of Palisade Bio will present at the Virtual Investor Innovations in Intestinal Health - Launching a Pivotal Phase 3 Study for Return of Postoperative Bowel Function Event on Friday, September 16, 2022 at 11:00 AM ET.

As part of the virtual event, the company will discuss its recently launched pivotal Phase 3 study designed to assess the safety and efficacy of LB1148 for postoperative return of bowel function. The Phase 3 study is designed as a multi-center, randomized, double-blind, parallel-group, placebo-controlled clinical trial set to enroll approximately 600 patients. The primary endpoint is time to recovery of the upper and lower gastrointestinal tract following surgery, defined as the time from the end of surgery to the toleration of food and first bowel movement. All patients enrolled in the study will undergo a scheduled bowel resection surgery that will include either laparotomy or minimally invasive surgical approaches. The clinical study will utilize the same dosing of LB1148 used in the company’s completed Phase 2 study in which LB1148 demonstrated a 1.1-day improvement in return of bowel function.

In addition to the moderated portion of the event, investors and interested parties will have the opportunity to submit questions. The company will answer as many questions as possible during the event.

A live video webcast of the Virtual Investor Innovations in Intestinal Health - Launching a Pivotal Phase 3 Study for Return of Postoperative Bowel Function Event will be available in the Latest Events and Presentations section of the Investor page of Palisade Bio website (palisadebio.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

About LB1148 LB1148 is an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. Evidence suggests that the release of digestive proteases contributes to the temporary loss of normal gastrointestinal function and the formation of postoperative adhesions. By inhibiting the activity of these digestive proteases, LB1148 has the potential to prevent damage to GI tissues, accelerate the time to the return of normal GI function, and shorten the duration of costly post-surgery hospital stays.

About Palisade Bio Palisade Bio is a late-stage biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier.

The Company’s lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In multiple clinical studies, LB1148 has demonstrated positive results in accelerating the time to return of postoperative bowel function, and the Company recently presented analysis that LB1148 reduced the incidence and severity of post-surgical abdominal adhesions. LB1148 is currently being evaluated in a Phase 3 clinical study for accelerating the return of postoperative bowel function and in a Phase 2 study for the prevention of post-surgical abdominal adhesions.

The Company believes that addressing the disruption of the intestinal barrier has the potential to fundamentally change the way diseases are treated and to establish new standards of patient care. For more information, please go to www.palisadebio.com.

Forward Looking Statements This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Palisade’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential to fundamentally change the way diseases are treated, the completion of enrollment for the Phase 3 study, the potential for the statistically significant Phase 3 data to allow for NDA approval, and the potential for LB1148 to establish the standard of care, if approved. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Palisade’s current expectations. Forward-looking statements involve risks and uncertainties. Palisade’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the company’s ability to advance its clinical programs, the uncertain and time-consuming regulatory approval process; the company’s ability to achieve additional financing to fund clinical development and the company’s ability to comply with the continued listing requirements for Nasdaq. Additional risks and uncertainties can be found in Palisade Bio’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Palisade expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Palisade’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Investor Relations Contact JTC Team, LLC Jenene Thomas 833-475-8247 PALI@jtcir.com

Less than five months after discouraging conversations with the U.S. Food and Drug Administration led Spero Therapeutics Inc. to pause work on a drug and lay off 110 people, the company is licensing that same drug to GSK plc for up to $291 million.

UBS's Colin Bristow raised his rating on the stock to Buy from Neutral, saying Well Street's expectations for sales of Mounjaro are too low.

The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.

This drugmaker has earned two new drug approvals in as many months, but its success isn't reflected in its market valuation yet.

Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.

Shares of Spectrum Pharmaceuticals Inc. were down 22.0% in premarket trading on Friday, the day after a Food and Drug Administration committee voted 9-4 that the benefits of the company's experimental lung-cancer drug do not outweigh the risks. The FDA is not required to follow the committee's advice when deciding when to approve a new drug but often does. The regulator is expected to make its decision on or before Nov. 24. Spectrum on Friday also announced a five-year debt financing plan with S

Shares of Bristol Myers Squibb (NYSE: BMY) were bouncing 3.4% higher as of 3:31 p.m. ET on Thursday after slipping a little earlier this week. Instead, today's move appeared to be the result of investors seeking relatively safe stocks as the Nasdaq Composite index and Russell 2000 small-cap index fell. Bristol Myers Squibb has seemed to be sort of a safe haven for investors throughout much of 2022.

By David Bautz, PhD NASDAQ:VIRI READ THE FULL VIRI RESEARCH REPORT Financial Update On September 23, 2022, Virios Therapeutics, Inc. (NASDAQ:VIRI) announced the closing of a previously announced underwritten public offering of 10 million shares of common stock at a price of $0.50 per share. The company raised gross proceeds of $5.0 million before deducting underwriting discounts, commissions, and

The social media giant’s head of community operations apologised at the inquest into the teenager’s death on Thursday.

Eli Lilly's blockbuster potential diabetes drug Mounjaro is "de-risked and transformative," an analyst said Thursday as he updated LLY stock.

The bear market hasn't dragged down Axsome Therapeutics (NASDAQ: AXSM). The biotech company specializes in treating central nervous system conditions. And it's been on a roll with good news -- and share performance -- in recent weeks.

Roche's (RHHBY) eye drug, Vabysmo and AstraZeneca's (AZN) asthma drug Tezspire get approval in Europe. The FDA approves expanded use of Lilly's (LLY) cancer drug, Retevmo.

AbbVie recently submitted a regulatory application in the European Union for Rinvoq to treat patients with a form of inflammatory bowel disease.

‘I happen to be a practising Roman Catholic. My church doesn’t even make that argument now,’ president says of abortion bans

Shares of Eli Lilly & Co. Inc. gained 2.5% in premarket trading on Thursday after UBS upgraded the stock to buy from neutral, saying Mounjaro, the company's newly approved Type 2 diabetes drug, could be "the biggest drug ever." UBS analysts predict peak sales of $25 billion if the therapy is also approved as a treatment for weight management in people with obesity. "Tirzepatide's robust efficacy in both obesity and [Type 2 diabetes] should drive sales into a range that we believe could see this

AngioDynamics took a risk when it spent $66 million to acquire new laser technology that had yet to hit the market. Three years later, that bet is starting to pay off.

DBV Technologies (DVBT) announces partial hold on phase III study of modified Viaskin Peanut 250 ??g patch, VITESSE, by the FDA. Stock declines.

Is Merck stock a buy as reports suggest it could put up $40 billion to acquire Seagen? Is MRK stock a buy right now?

Harriet Corr, seven, is regaining her strength after enduring years of coughing fits and a weakened immune system

Earlier this week Georgia Democratic gubernatorial nominee Stacey Abrams corrected a popular anti-abortion claim that a fetus has a heartbeat at six weeks of pregnancy. Abrams, who is running a campaign centered on abortion access to unseat Republican Gov. Brian Kemp spoke out against the medically incorrect term during a panel discussion in Atlanta on […]